New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?

3
2 Answers

Mednet Member
Rheumatology · Loyola University Medical Center

That is a good question. Adding on to Dr. @Dr. First Last's response, rituximab has been shown to cause hypogammaglobulinemia that can persist or worsen with ongoing therapy. In a study published by Barmettler and colleagues, 133 patients out of a cohort of 8633 patients had serum IgG levels checked...

How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?

2 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center

BRUIN trial enrolled patients with a median of 3 prior lines of treatment. The response rate with pirtobrutinib is close to 80%. However, overall PFS is about 1.5-2 years. So, most patients will eventually relapse after pirtobrutinib.It is possible that the use of pirtobrutinib in earlier lines of t...

Would involved site radiation therapy be recommended in a patient with POEMS syndrome whose myelopathy symptoms worsened after one cycle of CyBorD?

1
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · University Hospital Basel

I would swiftly treat this patient with a common schedule, for instance, 5 x 4 Gy. I do not see any risk of concurrent rituximab.

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

For primary CNS lymphoma, when do you refer for whole brain radiation therapy (WBRT)?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · Brigham and Women's Hospital

When data are limited, consensus guidelines tend to rely on the personal clinical experiences of the guideline committee members. That may explain the NCCN guidelines. Recently, remarkable progress has been noted in the treatment of CNS lymphoma with drugs alone. Ibrutinib is particularly effective ...

How would you approach a referral for concern for hemochromatosis with ferritin elevation but otherwise normal iron studies?

1 Answers

Mednet MemberInvited Expert
Hepatology · Keck School of Medicine of USC

Interesting questions, but lack of specifics about the degree of elevation and what constitutes normal iron studies makes it difficult to directly answer this question. However, there are well-recognized causes of elevated ferritin due to non-iron overloaded conditions, including increased apoferrit...

How would you approach the management of a patient with elevated iron saturation (60%) and ferritin (500s) with negative genetic testing for hemochromatosis?

1 Answers

Mednet MemberInvited Expert
Hepatology · Northwestern Memorial Hospital

I would approach this clinical scenario in the following manner: Always starting with good medical and family history first. Is there any history compatible with secondary hemochromatosis (i.e., history of blood or multiple iron transfusions)? Could the patient be tested for other non-282Y genetic ...

How would you manage HHT with ongoing epistaxis despite IV bevacizumab, with a history of superficial thrombosis?

2 Answers

Mednet MemberInvited Expert
Pulmonology · University of Colorado Health

This is a complex situation with a complex answer, and the patient would likely benefit from establishing care at one of the 30 HHT centers of excellence for a more thorough evaluation. If the patient mentioned has only had cautery, we would consider them seeing an ENT at an HHT center of excellence...

What are your top takeaways from ISTH 2025?

1
2 Answers

Mednet MemberInvited Expert
Hematology · University of Rochester School of Medicine and Dentistry

MAYARI trial - this trial was a single-arm trial for "non-severe" iTTP (excluding patients with significant cardiac or neurologic involvement) where PLEX was only used as a rescue therapy. Patients were started on caplacizumab and immunosuppression with steroids and rituximab. A large number of pa...

How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?

1
1 Answers

Mednet MemberInvited Expert
Medical Oncology · Abramson Cancer Center, Perelman School of Medicine University of Pennsylvania

For persistent cytopenias after FCR, the initial approach would be supportive care. If no recovery after 12 weeks, consideration should be for a bone marrow biopsy to evaluate for aplasia, an autoimmune process like PRCA, or early MDS. The therapy after the bone marrow would be based on the result. ...

How do you approach delivery planning in patients with T1 vWD?

2 Answers

Mednet MemberInvited Expert
Hematology · UPMC

For VWD, I recommend that the mode and timing of delivery be obstetric-based (i.e., the presence of VWD has no effect on the decision). If a CSX is needed, I consider an epidural safe if preceded by VWD-specific therapy. I base the duration of VWD-specific therapy on clinical history and 3rd-trimest...